<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02411942</url>
  </required_header>
  <id_info>
    <org_study_id>ADPG 1410</org_study_id>
    <nct_id>NCT02411942</nct_id>
  </id_info>
  <brief_title>Study Comparing Adapalene Gel 0.3% to Differin® and Both to a Placebo Control in Treatment of Acne Vulgaris</brief_title>
  <official_title>A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Adapalene Gel 0.3% to Differin® (Adapalene Gel 0.3%) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the therapeutic equivalence and safety of
      Adapalene Gel 0.3% and Differin® (adapalene gel 0.3%).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are to evaluate the therapeutic equivalence and safety of
      Adapalene Gel 0.3% and Differin® (adapalene gel 0.3%) in the treatment of acne vulgaris and
      to demonstrate the superiority of the efficacy of the test and reference products over the
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in inflammatory lesion counts</measure>
    <time_frame>Week 12</time_frame>
    <description>Percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in non-inflammatory lesion counts</measure>
    <time_frame>Week 12</time_frame>
    <description>Percent change from baseline to week 12 in the non-inflammatory (open and closed comedones) lesion counts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response of success</measure>
    <time_frame>Week 12</time_frame>
    <description>The proportion of subjects with a clinical response of success at week 12, success defined as an Investigator's Global Assessment score that is at least two grades less than the baseline assessment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">753</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Adapalene Gel 0.3%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adapalene Gel 0.3% (Taro Pharmaceuticals Inc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Differin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Differin® (adapalene gel 0.3%) (Galderma Laboratories, LP, US)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene Gel 0.3%</intervention_name>
    <description>Adapalene Gel 0.3% applied to the entire face once daily for 84 consecutive days</description>
    <arm_group_label>Adapalene Gel 0.3%</arm_group_label>
    <other_name>Adapalene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Differin®</intervention_name>
    <description>Differin® applied to the entire face once daily for 84 consecutive days</description>
    <arm_group_label>Differin®</arm_group_label>
    <other_name>Adapalene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (vehicle of the test product) applied to the entire face once daily for 84 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or non-pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis
             of acne vulgaris.

          -  Subjects aged 18 years and older must have provided written consent. Subjects aged 12
             to 17 years must have provided written assent accompanied by written consent from
             their legally acceptable representative. All subjects or their legally acceptable
             representatives must sign Health Insurance Portability and Accountability Act
             authorization.

          -  Must have a minimum of ≥ 25 non-inflammatory lesions and ≥ 20 inflammatory lesions and
             ≤ 2 nodulocystic lesions at baseline on the face.

          -  Must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as
             per the Investigator's Global Assessment.

        Exclusion Criteria:

          -  Female subjects who are pregnant, nursing or planning to become pregnant during study
             participation.

          -  Have a history of hypersensitivity or allergy to adapalene, retinoids and/or any of
             the study medication ingredients.

          -  Presence of any skin condition that would interfere with the diagnosis or assessment
             of acne vulgaris.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catawba Research</last_name>
    <role>Study Chair</role>
    <affiliation>http://catawbaresearch.com/contact/</affiliation>
  </overall_official>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2015</study_first_submitted>
  <study_first_submitted_qc>April 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adapalene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

